H.C. Wainwright assumed coverage of Rapt Therapeutics (RAPT) with a Buy rating and $6 price target The firm believes Rapt’s primary candidate, RPT904, operates through a commercially validated mechanism targeting immunoglobulin E, significantly reducing target risk given omalizumab approval in multiple indications, including food allergy, asthma, and chronic spontaneous urticaria.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPT:
- RAPT Therapeutics: Promising Clinical Developments and Strong Financial Performance Justify Buy Rating
- RAPT Therapeutics Reports Improved Q1 2025 Results
- Rapt Therapeutics reports Q1 EPS (8c), consensus (14c)
- Rapt Therapeutics appoints Jessica Savage as VP, clinical development
- RAPT Therapeutics Announces Board Restructuring in 2025